Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.
Haghiralsadat F, Amoabediny G, Naderinezhad S, Nazmi K, De Boer JP, Zandieh-Doulabi B, Forouzanfar T, Helder MN. Haghiralsadat F, et al. Among authors: naderinezhad s. Pharm Res. 2017 Dec;34(12):2891-2900. doi: 10.1007/s11095-017-2272-6. Epub 2017 Nov 6. Pharm Res. 2017. PMID: 29110283
A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery.
Haghiralsadat F, Amoabediny G, Helder MN, Naderinezhad S, Sheikhha MH, Forouzanfar T, Zandieh-Doulabi B. Haghiralsadat F, et al. Among authors: naderinezhad s. Artif Cells Nanomed Biotechnol. 2018 Feb;46(1):169-177. doi: 10.1080/21691401.2017.1304403. Epub 2017 Apr 4. Artif Cells Nanomed Biotechnol. 2018. PMID: 28376641
Preparation of PEGylated cationic nanoliposome-siRNA complexes for cancer therapy.
Haghiralsadat F, Amoabediny G, Naderinezhad S, Forouzanfar T, Helder MN, Zandieh-Doulabi B. Haghiralsadat F, et al. Among authors: naderinezhad s. Artif Cells Nanomed Biotechnol. 2018;46(sup1):684-692. doi: 10.1080/21691401.2018.1434533. Epub 2018 Feb 23. Artif Cells Nanomed Biotechnol. 2018. PMID: 29475393
CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation.
Wang Z, Hulsurkar M, Zhuo L, Xu J, Yang H, Naderinezhad S, Wang L, Zhang G, Ai N, Li L, Chang JT, Zhang S, Fazli L, Creighton CJ, Bai F, Ittmann MM, Gleave ME, Li W. Wang Z, et al. Among authors: naderinezhad s. Neoplasia. 2021 Nov;23(11):1147-1165. doi: 10.1016/j.neo.2021.09.005. Epub 2021 Oct 24. Neoplasia. 2021. PMID: 34706306 Free PMC article.